Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2005, p. 3648-3657, Vol. 25, No. 9
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.9.3648-3657.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Norman D. Rosenblum,2,3,5,7,8 and
Gregory E. Hannigan1,3,4*
Cancer Research Program,1 Program in Developmental Biology, Research Institute,2 Division of Nephrology,5 Department of Pediatric Laboratory Medicine, Hospital for Sick Children,3 Ontario Cancer Institute, University Health Network,6 Departments of Laboratory Medicine and Pathobiology,4 Physiology,7 Paediatrics, University of Toronto, Toronto, Ontario, Canada8
Received 26 October 2004/ Returned for modification 22 November 2004/ Accepted 1 February 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
While the presence of reciprocal tissue interactions limits the ability to interpret the primary effects of BMP7 in vivo, we have identified BMP7 functions in the inner medullary collecting duct 3 (IMCD-3) cell culture model of RBM (37, 39). IMCD-3 cells form tubule progenitors (i.e., morphogenesis) within 48 h of being cultured in collagen gels and respond to serum or purified growth factors in a manner identical to branching observed in embryonic kidney explants (3, 39). BMP7 acts to control IMCD-3 cell morphogenesis in a complex manner. High doses (>0.5 nM) inhibit morphogenesis in an Smad1-dependent manner, whereas low doses (<0.5 nM) stimulate progenitor formation in a Smad1-independent manner via effects on cell proliferation (37, 39). We have also demonstrated that stimulatory doses of BMP7 activate p38 mitogen-activated protein kinase (p38MAPK) and its target, activating transcription factor 2 (ATF-2), and that inhibiting p38MAPK activity blocks IMCD-3 morphogenesis (22). Our demonstration that Smad1 activity and p38MAPK/ATF-2 activation are inversely related suggests a cellular mechanism that integrates stimulatory and inhibitory BMP7 signal transduction pathways.
Integrins mediate essential cell-extracellular matrix (ECM) interactions during mammalian development but also transduce signals regulating cell proliferation, differentiation, and survival. In addition to growth factors, integrins contribute to epithelial-mesenchymal interactions during kidney organogenesis. Genetic ablation of the
8 integrin precludes formation of functional
8ß1 integrin in the mesenteric mesenchyme, resulting in severe defects of ureteric bud branching (34). The integrin-linked kinase (ILK) is an intracellular protein serine/threonine kinase that coordinates signaling by integrins and growth factors (6-8, 19), including insulin-like growth factor 1 (IGF-1) (29, 32), nerve growth factor (33), platelet-derived growth factor (2), and vascular endothelial growth factor (24, 44), in a variety of cell types. ILK binds directly to the cytoplasmic domains of ß integrin subunits (19). Additional protein interactions may function to physically link ILK with receptor tyrosine kinases (RTKs). ILK binds to PINCH, a LIM-only adaptor protein (46, 49). PINCH binds to another adaptor protein, Nck2, an SH2/SH3-containing protein that associates with ligand-activated epidermal growth factor (EGF) and platelet-derived growth factor receptors (47). In addition, ligand activation of these RTKs stimulates phosphoinositide 3'-OH kinase (PI 3-K) activity, and genetic or pharmacologic inhibition of PI 3-K abolishes both RTK- and integrin-mediated ILK activation (6, 7). The mechanism of ILK activation involves the major lipid product of PI 3-K activity, phosphoinositol-3,4,5-phosphate, which likely activates ILK by binding to the pleckstrin homology-like domain (9). Thus, PI 3-K dependent ILK activity exerts contextual effects governing epithelial-mesenchymal transition (43), myoblast differentiation, neurite outgrowth, and vascular morphogenesis.
BMP7 and
8 integrin regulate RBM in vivo, suggesting integrated growth factor and cell adhesion signaling during collecting duct morphogenesis. Here, we report that ILK displays an expression pattern in the embryonic mouse kidney that is consistent with a role in RBM. Infection of embryonic mouse kidney explants with adenovirus (Ad) expressing a dominant negative mutant of ILK markedly impaired formation of collecting ducts, further implicating ILK signaling in RBM. We therefore investigated the role of ILK in mediating BMP7-dependent renal epithelial cell morphogenesis, using the IMCD-3 model system. Treatment of IMCD-3 cells with stimulatory concentrations of BMP7 rapidly (<15 min) induced activation of ILK. Moreover, adenovirus-mediated expression of ILK markedly stimulated the formation of tubule progenitors and increased levels of phospho-p38MAPK and phospho-ATF-2. Conversely, a small molecule inhibitor of ILK, KP-392, abrogated IMCD-3 morphogenesis in three-dimensional cultures. In addition, infection with a dominant negative ILK mutant blocked BMP7-induced morphogenesis and inhibited the phosphorylation of p38MAPK and ATF-2. Our results identify a novel BMP7/ILK/p38MAPK/ATF-2 signaling pathway controlling epithelial cell morphogenesis.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Embryonic mouse kidney explant culture. Embryonic kidneys were surgically dissected from E13.5 pregnant mice and cultured as previously described (22). To evaluate the effect of ILK on RBM, adenoviruses expressing green fluorescent protein (GFP), ILK, or a dominant negative variant of ILK (28) were added to culture medium at 106, 105, and 104 PFU/ml, respectively, for 5 days. To verify infection efficiencies, fluorescent photos were taken just before explants were fixed for Dolichos biflorus agglutinin (DBA) staining. Selective staining of ureteric bud-derived structures in the whole-mount kidney specimens was achieved with fluorescein isothiocyanate-conjugated DBA (20 µg/ml) (Vector Laboratories, Burlington, Ontario, Canada) as previously described (16).
IMCD-3 cell culture, growth factor treatment, and morphogenesis assays. The IMCD-3 cell line is derived from the terminal inner medullary collecting duct of the simian virus 40 transgenic mouse. The IMCD-3 cell line retains several differentiated characteristics of the nephron, as previously described (40), and has been used as an in vitro model of collecting duct morphogenesis. IMCD-3 cells were grown in monolayers and maintained in Dulbecco's modified Eagle's medium-Ham's F12 medium (DMEM-F12) supplemented with 5% fetal bovine serum (Sigma), penicillin (100 U/ml), and streptomycin (100 U/ml) in 5% CO2 at 37°C.
To assay IMCD-3 cell morphogenesis, cells were suspended in type I collagen gels in 96-well tissue culture plates as previously described (39). Collagen gels were prepared on ice by mixing 4 µl of 1 M N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (Sigma), 8 µl of 1 M NaHCO3, 40 µl of DMEM-F12, 200 µl of 3.5-mg/ml rat type I collagen (Collaborative Biomedical Products), and 50,000 IMCD-3 cells. Aliquots (each, 50 µl/well) were seeded in 96-well culture plates. Gels were solidified at 37°C, and then 100 µl of medium containing 5% fetal bovine serum was added to each well. Cultures were maintained at 37°C in 5% CO2. BMP7 and epidermal growth factor stock solutions were prepared in DMEM-F12 and added at the indicated concentrations to the 5% fetal bovine serum-containing culture medium of newly established cultures of IMCD-3 cells. Cells were cultured in monolayers for biochemical studies or embedded in collagen gels for morphogenetic studies. After 48 h, gels were fixed in 4% formaldehyde in phosphate-buffered saline for 10 min at room temperature. Fixed gels were then washed four times in phosphate-buffered saline and imaged by differential interference contrast microscopy. Eight microscopic fields of equivalent dimensions were randomly selected and photographed at 100x magnification. Morphogenesis was quantified by counting the number of elongated, linear structures in these fields, presented as the number of independent linear structures per area of standard dimension. Assays were standardized for the number of cells seeded into the each collagen gel, as we have previously published (37, 39). The statistical significances between treatment differences were determined by a two-tailed, nonpaired Student's t test, using Prism software, version 3.0 (GraphPad Software, Inc.).
ILK immune complex kinase assay.
ILK immune complex kinase assays were carried out as described previously (19, 29). Protein concentrations were determined by Bradford assays (Bio-Rad, Richmond, Calif.). Cell lysates (0.25 to 1.0 mg of protein) were immunoprecipitated with 1 µg of affinity purified rabbit anti-ILK (Upstate Biotechnology, Inc.; catalogue no. 06-592) overnight at 4°C with rotation. Protein A-Sepharose (Sigma), preswollen in NP-40 lysis buffer (150 mM NaCl, 1% [vol/vol] NP-40, 0.5% [wt/vol] sodium deoxycholate, 50 mM HEPES [pH 7.4], 1 µg of leupeptin/ml, 1 µg of aprotinin/ml, 3 mM phenylmethylsulfonyl fluoride) was added for 2 h at 4°C to capture the antibodies. After two washes with NP-40 lysis buffer and two washes with kinase wash buffer (10 mM MgCl2, 10 mM MnCl2, 50 mM HEPES [pH 7.5], 0.1 mM sodium orthovanadate, 1 mM dithiothreitol), assays were performed directly on the protein A beads in a 25-µl reaction volume containing 10 mM MgCl2, 10 mM MnCl2, 50 mM HEPES (pH 7.5), 0.1 mM sodium orthovanadate, 2 mM sodium fluoride, 5 µCi of
-32P (Amersham, Piscataway, N.J.) and 2.5 µg of myelin basic protein (MBP) as substrate (Upstate Biotechnology, Inc.). Incubation was for 30 min at 30°C. The reaction was stopped with 10 µl of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) nonreducing stop buffer and heated for 5 min at 95°C. Phosphorylated MBP bands were visualized by autoradiography of dried SDS-10% PAGE gels, followed by quantitation in a PhosphorImager (Molecular Dynamics).
Adenovirus expression constructs. Adenoviruses expressing either wild-type or dominant negative ILK were constructed for expression in kidney explants and in IMCD-3 cells. Briefly, the full-length ILK coding sequence or the dominant negative point mutant, E359K, including a C-terminal myc-His epitope tag, was amplified from a pcDNA3.1 construct. EcoRV was used to digest the ILK-myc-His expression fragments for subcloning into pAd Trac (pAd Easy kit; Clontech). Bicistronic GFP and ILK expression allowed infection efficiencies to be confirmed visually by fluorescent microscopy. Viruses were amplified and CsCl gradient purified and titers were determined on HEK293 cells as described previously (28).
Antibodies and Western blotting.
For analysis of protein levels by Western blotting, SDS-PAGE gels were transferred to polyvinyldifluoride membranes (Immobilon-P; Millipore, Bedford, Mass.) in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol). Membranes were blocked in 5% milk in TBST (20 mM Tris [pH 7.5], 500 mM NaCl, 0.1% Tween 20). Affinity-purified primary polyclonal or monoclonal antibodies were used at a concentration of 1 µg/ml in Tris-buffered saline with 1% (wt/vol) bovine serum albumin (Fraction V; Sigma). Secondary antibodies were goat anti-mouse or anti-rabbit coupled to peroxidase, used at a dilution of 1/20,000 in TBST. Protein bands were visualized by chemiluminescence (ECL; Amersham) and exposure to Kodak X-Omat film, and signals were quantified with Kodak ID digital imaging software, version 2.0.2. Antibodies specific to phospho-glycogen synthase kinase 3ß (phospho-GSK3ß) (pSer9), protein kinase B (PKB) (Ser473), p38MAPK, ATF-2, phospho-p38MAPK (Thr180/182), and phospho-ATF-2 (Thr69/71) were purchased from Cell Signaling Technology, and antibodies recognizing total GSK3
/ß and PKB were obtained from Transduction Labs. A monoclonal antibody to the c-myc epitope was purchased from Santa Cruz Biotechnology.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
ILK activation, by growth factors or integrin-mediated cell adhesion, is dependent on the activity of PI 3-K. Thus, genetic or pharmacologic inhibition of PI 3-K signaling blocks activation of ILK by a variety of stimuli in epithelial cells, platelets, and myoblasts (9, 13, 32, 35, 36). To test for the involvement of PI 3-K activity in the BMP7 stimulation of ILK, we used the selective PI 3-K inhibitor LY294002. We pretreated IMCD-3, cultured in collagen gels, with LY294002 and then quantified induction of tubule progenitors by BMP7 and EGF. LY294002 pretreatment inhibited BMP7 induction of IMCD-3 tubule progenitors by 2.3 fold and inhibited EGF induction by 3.3 fold (Fig. 6A), suggesting that PI 3-K activity is required in BMP7- and ILK-dependent morphogenesis. We therefore tested whether LY294002 inhibited BMP7-dependent ILK activation by two independent assays of ILK activity. LY294003 effectively suppressed BMP7-activated GSK3ß Ser9 phosphorylation, a known cellular target of ILK (Fig. 6B). Similarly, pretreatment of IMCD-3 cells with LY294002 inhibited ILK activity as measured by ILK immune complex kinase assays (Fig. 6B). Our results indicate that BMP7 stimulation of both morphogenesis and ILK activity requires PI 3-K activity.
|
|
Our data suggested that ILK lies upstream of p38MAPK in the BMP7 morphogenetic pathway; therefore, we tested the effects of SB203580 p38MAPK inhibitor on BMP7-induced ILK activity. Cells were pretreated for 60 min with 0 or 10 µM SB203580 and subsequently treated for 15 min with 0.25 nM BMP7. As a measure of ILK activation, we assayed phospho-GSK3ß (pSer9) levels. SB203580 pretreatment did not inhibit BMP7-induced Ser9 phosphorylation (Fig. 7C). These lysates were also subjected to ILK immune complex kinase assays (28, 29), which showed lack of inhibition of BMP7-induced ILK activity by SB203580, whereas LY294002 inhibited ILK activity (Fig. 7D). These results place p38MAPK downstream of ILK activation by BMP7. Together with the results showing inhibition of BMP7-induced p38MAPK phosphorylation and morphogenesis by ILKE359K, these data identify a novel BMP7/ILK/p38MAPK/ATF-2 signaling axis mediating epithelial cell morphogenesis.
| DISCUSSION |
|---|
|
|
|---|
Using both embryonic kidney explants and the IMCD-3 cell culture model, we have previously shown opposite, dose-dependent effects of BMP7 in the regulation of epithelial cell morphogenesis (39). Low doses (<0.5 nM) stimulate and high doses (>0.5 nM) inhibit formation of IMCD-3 tubule progenitors. Interestingly, induction of ILK activity in our hands is maximal at the stimulatory dose (0.25 nM) of BMP7 (data not shown). We previously reported that inhibitory doses of BMP7 induce phosphorylation of Smad1 and formation of Smad1/Smad4 protein complexes and that a Smad1 dominant negative mutant selectively blocks inhibitory signaling (21, 37). Interestingly, the dominant negative Smad1 mutant potentiates BMP7 activation of p38MAPK/ATF-2 (22), suggesting that Smad1 acts to restrict ILK-p38MAPK signaling. We have previously shown that stimulatory and inhibitory pathways function in parallel in IMCD-3 cells (17); thus, it is likely that dose-dependent BMP7 signals are integrated at a point downstream of ILK-p38MAPK. However, a number of morphogenetic growth factors work through ILK in IMCD-3 cells, including hepatocyte growth factor (HGF) (our unpublished data), indicating that ILK is a point of stimulatory signal convergence. We do not know if ILK regulates RBM in vivo, as ILK null embryos die at E4.5, well before the onset of kidney development (42). Based on the results presented here, we speculate that developmentally regulated expression of morphogens, such as BMP7 and/or HGF (5), determines ILK-dependent ureteric bud branching during kidney organogenesis.
Our data place ILK upstream of p38MAPK in the BMP7 stimulatory pathway and suggest that BMP7 activates ILK in a PI 3-K-dependent manner. As discussed above, PI 3-K activity links a diverse complement of cell surface growth factor receptors and integrins to ILK signal transduction (6, 7). Both in vitro and in vivo studies indicate that activin-like ALK2 and ALK3 receptors mediate inhibitory BMP signaling in kidney epithelia (17, 21, 38); however, we do not know if stimulatory signaling is downstream of these ALKs or is mediated by a distinct receptor. Critical questions, thus, relate to the identify of the BMP7 stimulatory receptor and of the molecules that link it to PI 3-K activation. In this context, it will be important to determine whether the signaling adaptor, Nck2, plays a role in BMP7-ILK signaling.
Although ILK signaling has largely been studied in terms of ILK-PKB or ILK-GSK3ß interactions, studies have highlighted the importance of the ILK/p38MAPK signaling axis in regulating cell behavior. Indeed, the ILK/p38MAPK pathway is implicated in different morphogenetic events, since (as with IMCD-3 morphogenesis) inhibition of either kinase activity blocks induction of neurite outgrowth in mouse neuroblastoma cells (23). D'Amico et al. also showed that point mutation of an ATF-2 binding site or expression of a dominant negative ATF-2 mutant abolishes ILK-dependent transcriptional activation of the cyclin D1 gene in mammary epithelial cells (4). We note that BMP7 induction of p38MAPK and ATF-2 follows delayed kinetics relative to activation of ILK, suggesting indirect stimulation of p38MAPK by ILK. Thus, ILK regulation of p38MAPK/ATF-2 mediates diverse, context-dependent developmental processes.
The overlapping expression patterns of BMP7 (12, 14, 15, 31), ß1 integrin (1, 27), p38MAPK (20, 22), and ILK (Fig. 1) in embryonic kidneys suggest these molecules interact to regulate epithelial-mesenchymal interactions. Integrin-mediated UB cell-ECM interactions regulate branching in vitro and in vivo (10, 25, 51), and the requirement for a three-dimensional collagen matrix for IMCD-3 cell morphogenesis also implicates ß1 integrin signaling in this response. Functional integrity of ß1 integrins is required for proper development of the ureteric bud and elaboration of the collecting duct system. Genetic ablation of the
8 subunit in mice abolishes expression of
8ß1 integrin, leading to profound defects of RBM (34). Loss of
2ß1 integrin expression inhibits both collagen interaction and HGF-stimulated branching morphogenesis of MDCK kidney epithelial cells (41). Accordingly, blocking ß1 integrin function markedly inhibits branching of primary UB cells in three-dimensional collagen cultures and UB development in embryonic kidney explants (51). These results indicate the importance of ß1 integrin signaling in UB development, and our results reveal a key function of ILK in coordinating integrin and growth factor signaling during mammalian nephrogenesis. Interestingly, blocking ß1 integrin function suppresses ductal branching in the mammary epithelium of mice and inhibits HGF-induced branching of mammary epithelial cells in vitro (26). Moreover, expression of ILK in the mammary epithelium of transgenic mice induces formation of ductal branching structures (48), indicating that ILK signaling is likely to be of broad relevance in mediating epithelial branching during mammalian development.
| ACKNOWLEDGMENTS |
|---|
S.H. is the recipient of a studentship from the Research Training Committee of the Hospital for Sick Children. This work was supported by grants from the Canadian Institutes of Health Research (CIHR) (to N.D.R. and G.E.H.), and the National Cancer Institute of Canada (to G.E.H., with funds from the Terry Fox Run). G.E.H. was a Scholar of the CIHR.
| FOOTNOTES |
|---|
Present address: Musculoskeletal Disease Center, Jerry L. Pettis Memorial VA Medical Center Department of Medicine, Loma Linda University, Loma Linda, Calif. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Campana, W. M., R. R. Myers, and A. Rearden. 2003. Identification of PINCH in Schwann cells and DRG neurons: shuttling and signaling after nerve injury. Glia 41:213-223.[CrossRef][Medline]
3. Cantley, L. G., E. J. Barros, M. Gandhi, M. Rauchman, and S. K. Nigam. 1994. Regulation of mitogenesis, motogenesis, and tubulogenesis by hepatocyte growth factor in renal collecting duct cells. Am. J. Physiol. 267:F271-F280.
4. D'Amico, M., J. Hulit, D. F. Amanatullah, B. T. Zafonte, C. Albanese, B. Bouzahzah, M. Fu, L. H. Augenlicht, L. A. Donehower, K. Takemaru, R. T. Moon, R. Davis, M. P. Lisanti, M. Shtutman, J. Zhurinsky, A. Ben-Ze'ev, A. A. Troussard, S. Dedhar, and R. G. Pestell. 2000. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3ß and cAMP-responsive element-binding protein-dependent pathways. J. Biol. Chem. 275:32649-32657.
5. Davies, J. A., and C. E. Fisher. 2002. Genes and proteins in renal development. Exp. Nephrol. 10:102-113.[CrossRef][Medline]
6. Dedhar, D., B. Williams, and G. Hannigan. 1999. Integrin-linked kinase (ILK): a regulator of integrin and growth factor signalling. Trends Cell Biol. 9:319-323.[CrossRef][Medline]
7. Dedhar, S. 2000. Cell-substrate interactions and signaling through ILK. Curr. Opin. Cell Biol. 12:250-256.[CrossRef][Medline]
8. Dedhar, S., and G. E. Hannigan. 1996. Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Curr. Opin. Cell Biol. 8:657-669.[CrossRef][Medline]
9. Delcommenne, M., C. Tan, V. Gray, L. Rue, J. Woodgett, and S. Dedhar. 1998. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA 95:11211-11216.
10. Denda, S., L. F. Reichardt, and U. Müller. 1998. Identification of osteopontin as a novel ligand for the integrin
8ß1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol. Biol. Cell 9:1425-1435.
11. Dudley, A. T., K. M. Lyons, and E. J. Robertson. 1995. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev. 9:2795-2807.
12. Dudley, A. T., and E. J. Robertson. 1997. Overlapping expression domains of bone morphogenetic protein family members potentially account for limited tissue defects in BMP7 deficient embryos. Dev. Dyn. 208:349-362.[CrossRef][Medline]
13. Friedrich, E. B., S. Sinha, L. Li, S. Dedhar, T. Force, A. Rosenzweig, and R. E. Gerszten. 2002. Role of integrin-linked kinase in leukocyte recruitment. J. Biol. Chem. 277:16371-16375.
14. Godin, R. E., E. J. Robertson, and A. T. Dudley. 1999. Role of BMP family members during kidney development. Int. J. Dev. Biol. 43:405-411.[Medline]
15. Godin, R. E., N. T. Takaesu, E. J. Robertson, and A. T. Dudley. 1998. Regulation of BMP7 expression during kidney development. Development 125:3473-3482.[Abstract]
16. Grisaru, S., D. Cano-Gauci, J. Tee, J. Filmus, and N. D. Rosenblum. 2001. Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev. Biol. 231:31-46.[CrossRef][Medline]
17. Gupta, I. R., M. Macias-Silva, S. Kim, X. Zhou, T. D. Piscione, C. Whiteside, J. L. Wrana, and N. D. Rosenblum. 2000. BMP-2/ALK3 and HGF signal in parallel to regulate renal collecting duct morphogenesis. J. Cell Sci. 113:269-278.[Abstract]
18. Hannigan, G., A. A. Troussard, and S. Dedhar. 2005. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat. Rev. Cancer 5:51-63.[CrossRef][Medline]
19. Hannigan, G. E., C. Leung-Hagesteijn, L. Fitz-Gibbon, M. G. Coppolino, G. Radeva, J. Filmus, J. C. Bell, and S. Dedhar. 1996. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379:91-96.[CrossRef][Medline]
20. Hida, M., S. Omori, and M. Awazu. 2002. ERK and p38 MAP kinase are required for rat renal development. Kidney Int. 61:1252-1262.[CrossRef][Medline]
21. Hu, M. C., T. D. Piscione, and N. D. Rosenblum. 2003. Elevated SMAD1/beta-catenin molecular complexes and renal medullary cystic dysplasia in ALK3 transgenic mice. Development 130:2753-2766.
22. Hu, M. C., D. Wasserman, S. Hartwig, and N. D. Rosenblum. 2004. p38MAPK acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1. J. Biol. Chem. 279:12051-12059.
23. Ishii, T., E. Satoh, and M. Nishimura. 2001. Integrin-linked kinase controls neurite outgrowth in N1E-115 neuroblastoma cells. J. Biol. Chem. 276:42994-43003
24. Kaneko, Y., K. Kitazato, and Y. Basaki. 2004. Integrin-linked kinase regulates vascular morphogenesis induced by vascular endothelial growth factor. J. Cell Sci. 117:407-415.
25. Kanwar, Y. S., J. Wada, S. Lin, F. R. Danesh, S. S. Chugh, Q. Yang, T. Banerjee, and J. W. Lomasney. 2004. Update of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis. Am. J. Physiol. Renal Physiol. 286:F202-F215.
26. Klinowska, T. C., J. V. Soriano, G. M. Edwards, J. M. Oliver, A. J. Valentijn, R. Montesano, and C. H. Streuli. 1999. Laminin and ß1 integrins are crucial for normal mammary gland development in the mouse. Dev. Biol. 215:13-32.[CrossRef][Medline]
27. Korhonen, M., J. Ylanne, L. Laitinen, and I. Virtanen. 1990. Distribution of beta 1 and beta 3 integrins in human fetal and adult kidney. Lab. Investig. 62:616-625.[Medline]
28. Kumar, A. S., I. Naruszewicz, P. Wang, C. Leung-Hagesteijn, and G. E. Hannigan. 2004. ILKAP regulates ILK signaling and inhibits anchorage-independent growth. Oncogene 23:3454-3461.[CrossRef][Medline]
29. Leung-Hagesteijn, C., A. Mahendra, I. Naruszewicz, and G. E. Hannigan. 2001. Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin-linked kinase, ILK1. EMBO J. 20:2160-2170.[CrossRef][Medline]
30. Luo, G., C. Hofmann, A. L. Bronckers, M. Sohocki, A. Bradley, and G. Karsenty. 1995. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev. 9:2808-2820.
31. Martinez, G., Y. Mishina, and J. F. Bertram. 2002. BMPs and BMP receptors in mouse metanephric development: in vivo and in vitro studies. Int. J. Dev. Biol. 46:525-533.[Medline]
32. Miller, M. G., I. Naruszewicz, A. S. Kumar, T. Ramlal, and G. E. Hannigan. 2003. Integrin-linked kinase is a positive mediator of L6 myoblast differentiation. Biochem. Biophys. Res. Commun. 310:796-803.[CrossRef][Medline]
33. Mills, J., M. Digicaylioglu, A. T. Legg, C. E. Young, S. S. Young, A. M. Barr, L. Fletcher, T. P. O'Connor, and S. Dedhar. 2003. Role of integrin-linked kinase in nerve growth factor-stimulated neurite outgrowth. J. Neurosci. 23:1638-1648.
34. Muller, U., D. Wang, S. Denda, J. J. Meneses, R. A. Pedersen, and L. F. Reichardt. 1997. Integrin
8ß1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis. Cell 88:603-613.[CrossRef][Medline]
35. Persad, S., S. Attwell, V. Gray, M. Delcommenne, A. Troussard, J. Sanghera, and S. Dedhar. 2000. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. USA 97:3207-3212.
36. Persad, S., and S. Dedhar. 2003. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev. 22:375-384.[CrossRef][Medline]
37. Piscione, T. D., T. Phan, and N. D. Rosenblum. 2001. BMP7 controls collecting tubule cell proliferation and apoptosis via Smad1-dependent and -independent pathways. Am. J. Physiol. Renal Physiol. 280:F19-F33.
38. Piscione, T. D., and N. D. Rosenblum. 2002. The molecular control of renal branching morphogenesis: current knowledge and emerging insights. Differentiation 70:227-246.[CrossRef][Medline]
39. Piscione, T. D., T. D. Yager, I. R. Gupta, B. Grinfeld, Y. Pei, L. Attisano, J. L. Wrana, and N. D. Rosenblum. 1997. BMP-2 and OP-1 exert direct and opposite effects on renal branching morphogenesis. Am. J. Physiol. 273:F961-F975.
40. Rauchman, M. I., S. K. Nigam, E. Delpire, and S. R. Gullans. 1993. An osmotically tolerant inner medullary collecting duct cell line from an SV40 transgenic mouse. Am. J. Physiol. 265:F416-F424.
41. Saelman, E. U., P. J. Keely, and S. A. Santoro. 1995. Loss of MDCK cell alpha 2 beta 1 integrin expression results in reduced cyst formation, failure of hepatocyte growth factor/scatter factor-induced branching morphogenesis, and increased apoptosis. J. Cell Sci. 108:3531-3540.[Abstract]
42. Sakai, T., S. Li, D. Docheva, C. Grashoff, K. Sakai, G. Kostka, A. Braun, A. Pfeifer, P. D. Yurchenco, and R. Fassler. 2003. Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes Dev. 17:926-940.
43. Somasiri, A., A. Howarth, D. Goswami, S. Dedhar, and C. D. Roskelley. 2001. Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J. Cell Sci. 114:1125-1136.[Abstract]
44. Tan, C., S. Cruet-Hennequart, A. Troussard, L. Fazli, P. Costello, K. Sutton, J. Wheeler, M. Gleave, J. Sanghera, and S. Dedhar. 2004. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5:79-90.[CrossRef][Medline]
45. Tan, C., A. Mui, and S. Dedhar. 2002. Integrin-linked kinase regulates inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-
B-dependent manner. J. Biol. Chem. 277:3109-3116.
46. Tu, Y., F. Li, S. Goicoechea, and C. Wu. 1999. The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol. Cell. Biol. 19:2425-2434.
47. Tu, Y., F. Li, and C. Wu. 1998. Nck-2, a novel Src homology2/3-containing adaptor protein that interacts with the LIM-only protein PINCH and components of growth factor receptor kinase-signaling pathways. Mol. Biol. Cell 9:3367-3382.
48. White, D. E., R. D. Cardiff, S. Dedhar, and W. J. Muller. 2001. Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20:7064-7072.[CrossRef][Medline]
49. Wu, C. 1999. Integrin-linked kinase and PINCH: partners in regulation of cell-extracellular matrix interaction and signal transduction. J. Cell Sci. 112:4485-4489.[Abstract]
50. Yoganathan, N., A. Yee, Z. Zhang, D. Leung, J. Yan, L. Fazli, D. Kojic, P. Costello, M. Jabali, S. Dedhar, and J. Sanghera. 2002. Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties. Pharmacol. Ther. 93:233.[CrossRef][Medline]
51. Zent, R., K. T. Bush, M. L. Pohl, V. Quaranta, N. Koshikawa, Z. Wang, J. A. Kreidberg, H. Sakurai, R. O. Stuart, and S. K. Nigam. 2001. Involvement of laminin binding integrins and laminin-5 in branching morphogenesis of the ureteric bud during kidney development. Dev. Biol. 238:289-302.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|